Key Takeaways (AI-Generated)
Financial Performance
- Revenue grew 56% compared to Q1 2025, driven by Zepbound and Monjaro
- Key products grew by more than $7 billion year-over-year
- Non-GAAP earnings per share was $8.55 vs $3.34 in Q1 2025
- Monjaro and Zepbound combined global revenue was $12.8 billion
Business Highlights
- Foundeo approved by US FDA as first new incretin medicine for obesity indication
- Positive phase three data for multiple products inc...